The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

February 23, 2021

Study Completion Date

February 23, 2021

Conditions
Non-alcoholic Fatty Liver DiseaseNon-alcoholic Steatohepatitis
Interventions
DRUG

HEC96719

"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."

Trial Locations (1)

Unknown

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04422496 - The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter